These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 34716294

  • 1. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
    Miao X, Liu C, Jiang Y, Wang Y, Kong D, Wu Z, Wang X, Tian R, Yu X, Zhu X, Gong W.
    Cell Death Dis; 2021 Oct 29; 12(11):1020. PubMed ID: 34716294
    [Abstract] [Full Text] [Related]

  • 2. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W.
    Tumour Biol; 2013 Dec 29; 34(6):3637-48. PubMed ID: 23832540
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN.
    Oncotarget; 2014 May 15; 5(9):2372-89. PubMed ID: 24796583
    [Abstract] [Full Text] [Related]

  • 4. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, Cigliano A, Evert K, Ribback S, Dombrowski F, Pascale RM, Cossu A, Vidili G, Porcu A, Simile MM, Pes GM, Giannelli G, Gordan J, Wei L, Evert M, Cong W, Calvisi DF, Chen X.
    J Hepatol; 2017 Dec 15; 67(6):1194-1203. PubMed ID: 28733220
    [Abstract] [Full Text] [Related]

  • 5. Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer.
    Lee HS, Lee S, Cho KH.
    Int J Cancer; 2020 Nov 15; 147(10):2824-2837. PubMed ID: 32599680
    [Abstract] [Full Text] [Related]

  • 6. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression.
    Liang Z, Ge Y, Li J, Bai Y, Xiao Z, Yan R, An G, Zhang D.
    J Cancer Res Clin Oncol; 2024 Jul 09; 150(7):342. PubMed ID: 38980538
    [Abstract] [Full Text] [Related]

  • 7. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F, Hu B, Cheng JW, Sun YF, Zhou KQ, Wang PX, Guo W, Zhou J, Fan J, Chen Z, Yang XR.
    Cell Death Dis; 2020 Jul 24; 11(7):573. PubMed ID: 32709873
    [Abstract] [Full Text] [Related]

  • 8. Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer.
    Liu X, Xu W, Li L, Zhang Z, Lu M, Xia X.
    Int J Med Sci; 2024 Jul 24; 21(10):1814-1823. PubMed ID: 39113885
    [Abstract] [Full Text] [Related]

  • 9. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O.
    Clin Cancer Res; 2011 Apr 15; 17(8):2373-84. PubMed ID: 21372221
    [Abstract] [Full Text] [Related]

  • 10. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 15; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

  • 11. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 12. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
    Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B, Jücker M.
    Invest New Drugs; 2014 Dec 01; 32(6):1144-54. PubMed ID: 25152244
    [Abstract] [Full Text] [Related]

  • 13. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H, Zhang J, Zhang Y, Feng Q, Wang H, Li G, Jiang W, Li X.
    Gene; 2019 May 25; 698():50-60. PubMed ID: 30822475
    [Abstract] [Full Text] [Related]

  • 14. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
    Acharya B, Chaijaroenkul W, Na-Bangchang K.
    J Pharm Pharmacol; 2021 Aug 12; 73(9):1191-1200. PubMed ID: 33885818
    [Abstract] [Full Text] [Related]

  • 15. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
    PLoS One; 2012 Aug 12; 7(5):e37431. PubMed ID: 22662154
    [Abstract] [Full Text] [Related]

  • 16. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A, Li H, Li R, Lu L, Wu X.
    Oncol Rep; 2018 Oct 12; 40(4):2353-2362. PubMed ID: 30066933
    [Abstract] [Full Text] [Related]

  • 17. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, Wang J, Li B, Hu Y, Dong B, Shen L, Ji J, Gao J, Zhang X.
    Cell Death Dis; 2018 Jan 26; 9(2):123. PubMed ID: 29374144
    [Abstract] [Full Text] [Related]

  • 18. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN.
    Oncotarget; 2012 Nov 26; 3(11):1416-27. PubMed ID: 23232026
    [Abstract] [Full Text] [Related]

  • 19. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 20. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    van der Ploeg P, Uittenboogaard A, Thijs AMJ, Westgeest HM, Boere IA, Lambrechts S, van de Stolpe A, Bekkers RLM, Piek JMJ.
    Gynecol Oncol; 2021 Nov 31; 163(2):433-444. PubMed ID: 34253390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.